You are here » Home » Companies » Company Overview » Auro Laboratories Ltd

Auro Laboratories Ltd.

BSE: 530233 Sector: Health care
NSE: N.A. ISIN Code: INE292C01011
BSE LIVE 14:30 | 17 Jan 37.00 -1.00
(-2.63%)
OPEN

35.15

HIGH

38.25

LOW

35.00

NSE LIVE 05:30 | 01 Jan Stock Is Not Traded.
OPEN 35.15
PREVIOUS CLOSE 38.00
VOLUME 1321
52-Week high 48.05
52-Week low 17.10
P/E 16.89
Mkt Cap.(Rs cr) 23.05
Buy Price 37.00
Buy Qty 9.00
Sell Price 37.80
Sell Qty 22.00
OPEN 35.15
CLOSE 38.00
VOLUME 1321
52-Week high 48.05
52-Week low 17.10
P/E 16.89
Mkt Cap.(Rs cr) 23.05
Buy Price 37.00
Buy Qty 9.00
Sell Price 37.80
Sell Qty 22.00

Auro Laboratories Ltd. (AUROLABS) - Company History

Auro Laboratories is a manufacturer of Active Pharmaceutical Ingredients (API's), Intermediates and Generic Formulations. Auro Laboratories was founded and incorporated in 1992 at Mumbai, with a manufacturing facility located at Tarapur, 120 Km from Mumbai. Since inception, the company has focused on providing quality pharmaceuticals while maintaining high manufacturing standards. The company's primary focus has been on Anti-Diabetic Drugs, which is estimated to be one of the fastest growing therapeutic segments. Currently, it manufacture Metformin Hydrochloride and Glibenclamide and are on the anvil of introducing others within this segment. Additionally, it also undertake Toll/Custom Manufacturing for API's and Intermediates on contract basis. The manufacturing facility operates are per cGMP norms and has an installed capacity in excess of 500 Tonnes per annum. Auro laboratories has made its presence felt in international markets with a bulk of it production being exported to South East Asia, Middle East and several European Countries. Some of the countries the company exports to are Egypt, Germany, Malaysia, Singapore, South Africa, Brazil, Spain and United Kingdom. The company has received ISO 9001:2000 and WHO - cGMP certifications. It has also received CERTIFICATE OF SUITABILITY (COS) from the European Directorate of Quality Medicine (EDQM) in September 2006.